Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Download Data

Monte Rosa Therapeutics Inc Operating Cash Flow 5 year CAGR for the quarter ending March 31, 2024

Monte Rosa Therapeutics Inc Operating Cash Flow 5 year CAGR is NA for the quarter ending March 31, 2024. Operating Cash Flow is the net cash generated from a company's core operations, including revenue, expenses, and changes in working capital. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Monte Rosa Therapeutics Inc Operating Cash Flow for the quarter ending March 31, 2023 was USD -23.41 M, a 14.59% change year over year.
Monte Rosa Therapeutics Inc Operating Cash Flow for the quarter ending March 31, 2022 was USD -27.40 M, a -98.36% change year over year.
Monte Rosa Therapeutics Inc Operating Cash Flow for the quarter ending March 31, 2021 was USD -13.81 M, a -309.21% change year over year.
Monte Rosa Therapeutics Inc Operating Cash Flow for the quarter ending March 31, 2020 was USD -3.38 M.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends